Characteristic | Characteristic Detail | Studies (N = 56) | References |
---|---|---|---|
Prescribing Domain* | Initiating | Â | Â |
 |    Before drug selection | 26 | |
 |    After drug selection | 12 | |
 | Monitoring | 23 | |
 | Stopping | 3 | |
Geographic Setting | North America | 39 | [16–18, 20, 21, 23, 27–30, 32, 33, 35–45, 47, 49–59, 62, 65–67] |
 | Europe | 15 | |
 | Other | 2 | |
Target | Physicians | 35 | [19–21, 24–27, 29–34, 37, 39, 42, 44–48, 56, 57, 59–69, 71] |
 | Physicians/other health care professionals | 21 | [16–18, 22, 23, 28, 35, 36, 38, 40, 41, 43, 49–55, 58, 70] |
Initiation of CDSS | System initiated | 39 | [16, 18, 20–30, 32, 33, 35–37, 40–53, 58, 60, 62, 63, 66, 67, 70] |
 | User initiated | 14 | |
 | Mixed/Unclear | 3 | |
Clinical Setting | Ambulatory | 37 | [16–20, 22–28, 31, 32, 35–39, 41–43, 46, 48, 51–54, 58, 59, 61–64, 67–69] |
 | Institutional | 16 | [21, 29, 30, 33, 34, 44, 45, 47, 49, 50, 55–57, 65, 66, 71] |
 | Both | 3 | |
Implementation strategy | CDSS only | 37 | [17, 21, 22, 27–29, 34, 36, 37, 40–57, 59–65, 68, 69, 71] |
 | Multi-faceted | 19 | |
Clinical Area* | Cardiovascular disease | 19 | |
 | Antibiotic therapy | 9 | |
 | Vaccinations | 9 | |
 | Respiratory conditions | 9 | |
 | Anticoagulant therapy | 12 | |
 | Elderly (multiple conditions and drugs) | 4 | |
 | Osteoporosis | 2 | |
 | Other | 11 |